Topics

Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological Cancers

08:00 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Apristor® (onapristone extended release), a full progesterone receptor antagonist, is being studied in patients with rare gynecological cancers who are Progesterone Receptor Positive (PgR+) ...

Other Sources for this Article

For Context Therapeutics:
Company Contact:
Martin Lehr
Co-Founder & Chief Executive Officer
info@contexttherapeutics.com
or
Investor Contact:
Solebury Trout
Michael Levitan
mlevitan@troutgroup.com

NEXT ARTICLE

More From BioPortfolio on "Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological Cancers"

Quick Search

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...